Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 52,034,400 | 61,060,764 | 94,901,046 | 70,723,214 | 115,038,771 | 393,758,195 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 52,034,400 | 61,060,764 | 94,901,046 | 70,723,214 | 115,038,771 | 393,758,195 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 169,097,459 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 224,660,736 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 52,034,400 | 61,060,764 | 94,901,046 | 70,723,214 | 115,038,771 | 393,758,195 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 556,550 | 268,801 | 302,728 | 378,725 | 2,090,669 | 3,597,473 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 116,870 | 58,024 | 95,299 | 104,653 | 374,846 | |
| 11 | Total support. Add lines 7 through 10 | 397,730,514 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| THE ORGANIZATIONS MISSION | FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS ORGANIZED AND OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, DEDICATED TO STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH, SEQUENCING AND BIOINFORMATICS, WHOSE MEMBERS INCLUDE LEADING ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS. IT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) FOSTERING INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING WORLD CLASS SCIENTIFIC TALENT TO LEAD THE SCIENTIFIC DEVELOPMENT OF THE ORGANIZATION; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGCS SCIENTIFIC PROGRAM AND GENOMIC RESEARCH; (IV) DEVELOPING ADVANCED BIOINFORMATICS CAPABILITIES BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATIONS FACILITIES; (V) ADVANCING RESEARCH TO SUPPORT THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; AND (VII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. STRATEGIC PLAN FORM 990, PART III, LINE 3: IN THE SUMMER OF 2018, NYGC LEADERSHIP UNDERTOOK A STRATEGIC PLANNING PROCESS TO CONSIDER ITS GROWTH FROM A 'START-UP' GENOME CENTER TO A WORLD-CLASS GENOMIC SCIENCE INSTITUTE. BUILDING ON ITS FOUNDATION, NYGC EMBRACED A NEW SCIENTIFIC DIRECTION, ONE DESIGNED TO POSITION THE ORGANIZATION AT THE FOREFRONT OF DISEASE-BASED GENOMIC RESEARCH, EXPRESSED IN A NEW, FOCUSED MISSION. NYGC'S NEW STRATEGIC DIRECTION LEVERAGES THE STRENGTHS AND CAPABILITIES DEVELOPED SINCE NYGCS FOUNDING, AND ENRICHES ITS LOCAL, NATIONAL, AND INTERNATIONAL COLLABORATIONS. NYGC IS NOW FOCUSING ON RESEARCH IN THREE KEY AREAS WHERE IT CAN MAKE A DIFFERENCE: NEURODEGENERATIVE DISEASES (ALS, ALZHEIMERS, PARKINSONS, HUNTINGTONS); NEUROPSYCHIATRIC DISEASES (AUTISM, SCHIZOPHRENIA, BIPOLAR); AND CANCER THROUGH THE DEVELOPMENT OF NOVEL STATISTICAL METHODS, POPULATION LEVEL ANALYSES, AND APPLICATION OF NOVEL TECHNOLOGIES. THIS STRATEGY NOT ONLY ENABLES DEEP EXPLORATION OF THE GENOMIC UNDERPINNINGS OF THESE DISEASES BUT ALSO DRIVES THE DEVELOPMENT OF INNOVATIVE SEQUENCING AND COMPUTATIONAL METHODS WITH POTENTIAL WIDE-RANGING APPLICATIONS, AND WILL BENEFIT NYGC, ITS MEMBER INSTITUTIONS, AND THE WIDER BIOMEDICAL RESEARCH COMMUNITY. |
| PROGRAM SERVICE ACCOMPLISHMENTS | FORM 990, PART III, LINE 4A, LINE 4B, LINE 4C, LINE 4D: NYGC IS AN INDEPENDENT, NONPROFIT ACADEMIC RESEARCH INSTITUTION WITH THE MISSION OF ADVANCING CLINICAL CARE THROUGH TRANSFORMATIVE GENOMIC RESEARCH. NYGCS WORK BUILDS ON THE STRENGTHS AND CAPABILITIES THAT NYGC HAS DEVELOPED SINCE ITS FOUNDING IN 2010 AND AUGMENTS RESEARCH BEING CONDUCTED BY NYGC MEMBER INSTITUTIONS. COLLABORATING WITH PREMIER ACADEMIC, MEDICAL AND INDUSTRY LEADERS ACROSS THE GLOBE, NYGC IS CONDUCTING DISEASE-BASED GENOMIC RESEARCH IN AREAS WHERE IT HAS DEVELOPED A SIGNIFICANT AND SUCCESSFUL TRACK RECORD, INCLUDING NEURODEGENERATIVE DISEASES SUCH AS ALS, NEUROPSYCHIATRIC DISEASES, PARTICULARLY AUTISM, AND CANCER, FOCUSING ON UNDERSERVED POPULATIONS AND RARE CANCERS, AMONG OTHERS. THROUGH INNOVATIVE RESEARCH AND GENOMIC DISCOVERY, NYGC'S GOAL IS TO ADVANCE HUMAN HEALTH AND THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS THAT TREAT DISEASE. NYGC AND ITS MEMBER INSTITUTIONS AND PARTNERS ARE UNITED IN THIS UNPRECEDENTED COLLABORATION OF TECHNOLOGY, SCIENCE AND MEDICINE, DESIGNED TO HARNESS THE POWER OF INNOVATION AND DISCOVERIES TO ADVANCE GENOMIC DISCOVERIES. THEIR SHARED OBJECTIVE IS THE ACCELERATION OF MEDICAL GENOMICS AND PRECISION MEDICINE TO BENEFIT PATIENTS AROUND THE WORLD. NYGC'S INNOVATION, RESEARCH AND QUALITY MAKE IT A UNIQUE AND STRONG COLLABORATIVE PARTNER. IN 2018, NYGC LAUNCHED A NEW STRATEGY THAT LEVERAGES ITS CORE STRENGTHS IN WHOLE GENOME SEQUENCING AND ANALYSIS, SINGLE-CELL TECHNOLOGY AND BIOINFORMATICS. A CRITICAL ELEMENT OF THE NEW SCIENTIFIC MISSION BUILDS ON THE FOUNDATION OF THE COLLABORATIVE RESEARCH PROJECTS AMONG NYGC FACULTY AND STAFF SCIENTISTS WITH MEMBER INSTITUTIONS, AN AFFILIATE MEMBERSHIP PROGRAM, DISEASE- AND TECHNOLOGY-CENTERED WORKING GROUPS AND INDUSTRY PARTNERS. IN 2018, NYGC EXPANDED ITS AFFILIATE MEMBERSHIP PROGRAM, WHICH NOW TOTALS 69 MEMBERS, HAILING FROM 14 ACADEMIC INSTITUTIONS ACROSS THE COUNTRY. RESEARCH AND FACULTY --------------------- SINCE ITS INCEPTION, NYGC HAS ATTRACTED WORLD-CLASS SCIENTISTS WHOSE GENOMIC EXPERTISE - INCLUDING SINGLE CELL GENOMICS, GENOME ENGINEERING, POPULATION AND EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, STATISTICS, COMPUTATIONAL BIOLOGY AND BIOENGINEERING - BRING A MULTIDISCIPLINARY AND IN-DEPTH APPROACH TO THE EVOLVING FIELD OF GENOMICS. NYGC'S FACULTY SUPPORT NYGC'S SCIENTIFIC VISION THROUGH THE ADVANCEMENT OF GENOMIC MEDICINE. FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT THE NYGC'S INSTITUTIONAL FOUNDING MEMBERS TO PROMOTE COLLABORATION, STRENGTHEN RESEARCH CAPABILITIES, ADVANCE ACADEMIC LEADERSHIP, AND ENHANCE ABILITY TO HELP SOLVE HUMAN DISEASES. IN 2018, NYGC MANAGED 35 GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH). NYGC'S RESEARCHERS ARE WORKING WITH ITS MEMBER INSTITUTIONS AND AN ARRAY OF COLLABORATIVE PARTNERS TO ADDRESS THE FUNDAMENTAL CHALLENGE IN PRECISION MEDICINE: UNDERSTANDING THE RELATIONSHIP BETWEEN DNA SEQUENCE VARIATION AND MECHANISMS FOR HUMAN DISEASES, RANGING FROM CANCER TO AUTISM TO NEURODEGENERATIVE DISEASE. NYGC RESEARCHERS PUBLISHED MORE THAN 50 STUDIES IN LEADING SCIENTIFIC JOURNALS IN 2018, FUELING MOMENTUM FOR IMPORTANT COLLABORATIVE WORK. THEY COMPLETED MORE THAN 639 PROJECTS, COLLABORATING WITH 193 INVESTIGATORS FROM 85 INSTITUTIONS ACROSS THE GLOBE. NYGC FACULTY MEMBERS FOCUS THEIR RESEARCH IN ADVANCED GENOMICS STUDY. WHILE THE FIELD OF SINGLE-CELL SEQUENCING IS RAPIDLY EXPANDING, SIGNIFICANT COMPUTATIONAL CHALLENGES REMAIN, PARTICULARLY WHEN ANALYZING MULTIPLE DATASETS. IN 2018, NYGC CORE FACULTY MEMBER RAHUL SATIJA, PHD, WHO HOLDS A JOINT APPOINTMENT AT NEW YORK UNIVERSITY (NYU), AND HIS LAB MADE ADVANCES IN ADDRESSING THIS CHALLENGE BY DEVELOPING AND DEPLOYING A NEW ALGORITHM THAT ALIGNS MULTIPLE SEQUENCING DATASETS WITH SINGLE-CELL RESOLUTION. THE NEW METHOD HAS IMPLICATIONS FOR BETTER UNDERSTANDING HOW DIFFERENT GROUPS OF CELLS CHANGE DURING DISEASE PROGRESSION, IN RESPONSE TO DRUG TREATMENT, OR ACROSS EVOLUTION. THE TEAMS DESCRIPTION OF THEIR METHOD WAS PUBLISHED IN "NATURE BIOTECHNOLOGY." IN THE FALL OF 2018, THE SATIJA LAB WAS SELECTED TO BE A RECIPIENT OF NIHS FIRST SET OF RESEARCH FUNDING AWARDS FOR THE HUMAN BIOMOLECULAR ATLAS PROGRAM (HUBMAP) TO DEVELOP AN OPEN, GLOBAL FRAMEWORK SUPPORTING EFFORTS TO BUILD A MAP OF CELLS WITHIN THE ADULT HUMAN BODY. THE LABS AWARD-WINNING PROJECT, ENTITLED "COMPREHENSIVE REFERENCE MAP CONSTRUCTION, GEOLOCATION AND DATA INTEGRATION FOR HUBMAP HIVE," ESTABLISHED A NYGC-LED 'MAPPING CENTER' FOR THE HUBMAP CONSORTIUM. WITH THIS AWARD, NYGC BECOMES ONE OF FIVE NIH-DESIGNATED HIVE CENTERS, ALONG WITH THE CARNEGIE MELLON UNIVERSITY, INDIANA UNIVERSITY BLOOMINGTON, HARVARD MEDICAL SCHOOL, AND THE UNIVERSITY OF SOUTH DAKOTA. NYGC CORE FACULTY MEMBER TUULI LAPPALAINEN, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, WAS RECIPIENT OF THE 2018 LEENA PELTONEN PRIZE FOR EXCELLENCE IN HUMAN GENETICS IN RECOGNITION OF HER CONTRIBUTIONS TO THE HUMAN GENETICS FIELD. IN FINDINGS PUBLISHED IN "NATURE GENETICS," DR. LAPPALAINEN AND HER RESEARCH TEAM PROVIDED EVIDENCE FOR MODIFIED PENETRANCE, IN WHICH GENETIC VARIANTS THAT REGULATE GENE ACTIVITY MODIFY THE DISEASE RISK CAUSED BY PROTEIN-CODING GENE VARIANTS. THEY ALSO LINKED MODIFIED PENETRANCE TO SPECIFIC DISEASES AT THE GENOME-WIDE LEVEL. THE TEAMS FINDINGS HAVE EXCITING IMPLICATIONS FOR FUTURE PREDICTION OF THE SEVERITY OF SERIOUS DISEASES SUCH AS CANCER AND AUTISM SPECTRUM DISORDER. NYGCS CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE'S ALS CONSORTIUM, LED BY HEMALI PHATNANI, PHD., DIRECTOR, CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE, HAS GROWN TO 30 MEMBERS IN FIVE COUNTRIES IN JUST A FEW YEARS SINCE ITS INCEPTION. IT SERVES AS AN ORGANIZING HUB OF ALS DATA COLLECTION AND ANALYSIS WITHIN THE RESEARCH COMMUNITY. THE RESULT IS ALS DATA SHARING ON AN UNPARALLELED SCALE EMPOWERING AN INTEGRATED APPROACH TO WORKING TOWARD NEW TREATMENTS AND EFFECTIVE THERAPIES FOR ALS. THROUGH THIS GLOBAL COLLABORATION, CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS SHARE AN EVER-GROWING RESOURCE OF GENOMIC SEQUENCING AND CLINICAL DATA. BY THE END OF 2018, OVER 3,000 SAMPLES FROM ALS PATIENTS, MORE THAN HALFWAY TO THE GOAL OF 5,000 SAMPLES, HAVE BEEN SEQUENCED AND ANALYZED. THIS DATASET, ONE OF THE LARGEST COHORTS IN THE WORLD, IS AVAILABLE TO RESEARCHERS. |
| CANCER | ------- UTILIZING STATE-OF-THE-ART TECHNOLOGIES AND AN UNPRECEDENTED LEVEL OF COLLABORATION WITH THE LEADING RESEARCH INSTITUTIONS IN NEW YORK, NYGC IS ENGAGED IN MANY CUTTING-EDGE INVESTIGATIONS INTO THE ORIGINS, DIAGNOSIS, AND EVOLUTION OF CANCER. TO ADVANCE COLLABORATIVE EFFORTS ON CANCER GENOMICS, NOBEL LAUREATE HAROLD VARMUS, MD, SENIOR ASSOCIATE CORE MEMBER, NYGC, AND LEWIS THOMAS UNIVERSITY PROFESSOR OF MEDICINE, WEILL CORNELL MEDICINE (WCM), ESTABLISHED THE NEW YORK CANCER GENOMICS RESEARCH NETWORK. IN 2018, DR. VARMUS CONVENED MONTHLY MEETINGS AT NYGC WITH LEADING CANCER RESEARCHERS AND CLINICIANS FROM NYGC'S INSTITUTIONAL FOUNDING MEMBERS AND OTHER KEY ACADEMIC INSTITUTIONS FROM AROUND THE WORLD. THE OBJECTIVE OF THIS MULTIDISCIPLINARY APPROACH IS TO HELP SET CRITICAL PRIORITIES IN TRANSLATING GENOMIC SCIENCE INTO MORE EFFECTIVE TREATMENT OPTIONS FOR ALL CANCER PATIENTS. THE NETWORK INITIATED A CITY-WIDE PROJECT TO ENSURE THAT ADVANCES IN GENOMICS AND PRECISION MEDICINE CAN BE APPLIED TO ALL POPULATIONS AND EXPAND KNOWLEDGE OF THE GENETIC VARIATIONS THAT CONTRIBUTE TO CANCER. NAMED "POLYETHNIC-1000," THE PROJECT UTILIZES THE GREATER NEW YORK AREA'S ETHNIC DIVERSITY TO ADDRESS SEVERAL IMPORTANT SCIENTIFIC QUESTIONS ABOUT THE ROLE OF ETHNICITY IN ONCOLOGY AND OFFER GENOMIC SERVICES DURING THE PROVISION OF CANCER CARE TO ALL POPULATIONS. THIS INITIATIVE INVOLVES PATIENTS AND STAFF AT 16 ACADEMIC HEALTH CENTERS AND PARTNER HOSPITALS IN THE NEW YORK CITY REGION. PHASE ONE, A RETROSPECTIVE STUDY OF 100 SAMPLES FROM COLLABORATING CENTERS, OF THE THREE-PHASE PROJECT BEGAN IN THE LAST QUARTER OF 2018. PHASE TWO, A PROSPECTIVE STUDY, WILL LAUNCH IN MID-2019. NYGC FACULTY ARE WORKING TO ADVANCE GENOMIC INSIGHTS INTO CANCER IN THEIR LABORATORIES. IN 2018, DAN LANDAU, MD, PHD, A NYGC CORE FACULTY MEMBER WHO HOLDS A JOINT APPOINTMENT AT WCM, RECEIVED THE NIH "NEW INNOVATOR" AWARD FOR LIQUID BIOPSY RESEARCH. WITH THE SUPPORT OF THIS PRESTIGIOUS AWARD, DR. LANDAU WILL CONTINUE HIS CRITICAL EFFORTS TO DEVELOP TOOLS FOR LIQUID BIOPSY, THE EARLY-STAGE DETECTION OF CANCER THROUGH THE MEASUREMENT OF TUMOR DNA IN A PATIENT'S BLOOD. DR. LANDAU IS WORKING WITH AN ARRAY OF COLLABORATORS TO GUIDE DRUG COMBINATIONAL THERAPIES AND TEST NEW DRUG TREATMENTS WITH THE AIM OF OPTIMIZING TREATMENT BY CONTINUOUSLY MONITORING GENETIC CHANGES IN CANCER CELLS IN REAL TIME. MARCIN IMIELINSKI, MD, PHD, A NYGC CORE FACULTY MEMBER WHO HOLDS A JOINT APPOINTMENT AT WCM, CONTINUES HIS ILLUMINATING WORK IN IDENTIFYING AND EXPLORING THE GENETIC SIGNATURES THAT SERVE AS BIOMARKERS THAT CAN IMPROVE CANCER DIAGNOSIS AND TREATMENT. WITH STARR CANCER CONSORTIUM SUPPORT, DR. IMIELINSKI SERVES AS CO-PRINCIPAL INVESTIGATOR AND WORK WITH RESEARCHERS FROM WCM AND MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC) TO EXPLORE THE POTENTIAL OF VARIOUS STRUCTURAL VARIANT MUTATIONAL SIGNATURES AS BIOMARKERS OF CHEMOTHERAPY RESPONSE AND RESISTANCE. NYGC CORE FACULTY MEMBER NEVILLE SANJANA, PHD, WHO HOLDS A JOINT APPOINTMENT AT NYU AND NYU MEDICAL SCHOOL, WROTE THE PRIZE-WINNING ESSAY "A GENOME LABORATORIES TO CATCH AND UNDERSTAND CANCER," WHICH WAS ON THE COVER OF "SCIENCE TRANSLATIONAL MEDICINE." IN 2018, DR. SANJANA WAS SELECTED BY THE AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (AAAS) FOR ITS PRESTIGIOUS AAAS MARTIN AND ROSE WACHTEL CANCER RESEARCH AWARD. THE AWARD RECOGNIZES AND SUPPORTS DR. SANJANA'S NOVEL USE OF GENE EDITING CALLED "TWO-CELL TYPE" CRISPR TO BETTER UNDERSTAND WHY IMMUNOTHERAPY FAILS IN MOST CANCER PATIENTS. THE GROUNDBREAKING TECHNIQUE IS A SUCCESSFUL MODEL FOR RESEARCHERS TO INTERROGATE OTHER IMMUNE CELL TYPES AND OTHER DISEASE WHERE INTERACTION BETWEEN MULTIPLE CELLS IS IMPORTANT. DR. SANJANA'S FINDINGS COULD HELP CLINICIANS DEVELOP MORE PERSONALIZED TREATMENT TO ACHIEVE BETTER RESPONSE RATES. NYGC'S COMPUTATIONAL BIOLOGY LAB SCIENTISTS CONTRIBUTED THEIR BIOINFORMATICS EXPERTISE TO MANY IMPORTANT SCIENTIFIC PUBLICATIONS IN 2018, INCLUDING THE FOLLOWING CANCER STUDIES: *A COLLABORATION WITH MSKCC, REPORTED IN "PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA," THAT IDENTIFIES ONE WAY THAT LUNG CANCER CELLS OUTSMART DRUGS THAT BLOCK A PROTEIN CALLED EGFR, A COMMON TARGETED DRUG THERAPY. THESE FINDINGS MAY HELP PAVE THE WAY FOR IMPROVED TREATMENTS. *A STUDY LED BY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, PUBLISHED IN "GENOME RESEARCH," THAT IDENTIFIES SEVERAL GENETIC MUTATIONS AS DISEASE DRIVERS IN THE SUBSET OF ORAL CANCERS TARGETED BY THE HUMAN PAPILLOMAVIRUS (HPV). RESEARCHERS ANTICIPATE THAT THESE RESULTS WILL FOSTER ADVANCES IN DIAGNOSIS, THERAPY, AND THE GENERAL UNDERSTANDING OF THE ROLE OF HPV IN THE DEVELOPMENT OF ORAL CANCERS. *A COLD SPRING HARBOR LABORATORY-LED ANALYSIS, PUBLISHED IN "CANCER DISCOVERY," THAT COMPARED PATIENT-DERIVED INDIVIDUAL ORGANOIDS - HOLLOW SPHERES OF CELLS CULTURED FROM TUMORS - WITH THEIR ASSOCIATED PRIMARY TUMORS, BY WHOLE-GENOME SEQUENCING AND RNA-SEQUENCING. THE STUDY DETERMINED NOVEL DRIVER MUTATIONS AND GENE SIGNATURES THAT PREDICT SENSITIVITY TO DIFFERENT TYPES OF CHEMOTHERAPIES. THESE FINDINGS WILL HELP FACILITATE PERSONALIZED TREATMENTS FOR PANCREATIC CANCER PATIENTS. |
| NEUROPSYCHIATRIC DISEASES | --------------------------- NYGC IS BUILDING UPON ITS EXPERTISE IN AUTISM GENOMIC RESEARCH TO STUDY A RANGE OF RELATED NEUROPSYCHIATRIC DISORDERS THAT HAVE GENES IMPLICATED IN COMMON, INCLUDING SCHIZOPHRENIA AND BIPOLAR DISEASE. BY YEAR-END 2018, 19,077 WHOLE GENOMES OF AUTISM PATIENTS AND THEIR FAMILIES WERE SEQUENCED BY NYGC. THIS CRITICAL, GROWING DATASET AIDS IN THE ONGOING INVESTIGATIONS OF NYGC FACULTY AND STAFF SCIENTISTS, MEMBER INSTITUTIONS, AND OTHER COLLABORATIVE PARTNERS. THIS WORK IS PART OF A FOUR-YEAR GRANT OF $40 MILLION FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, A DIVISION OF THE NATIONAL INSTITUTES OF HEALTH, WHICH WAS AWARDED TO NYGC IN 2015 TO CREATE A CENTER FOR COMMON DISEASE GENOMICS. THIS COLLABORATIVE LARGE-SCALE GENOME SEQUENCING PROGRAM IS FOCUSED ON ADVANCING UNDERSTANDING OF AUTISM. NYGC'S FACULTY ARE ALSO ENGAGED IN THIS WORK. DR. SANJANA RECEIVED THE YOUNG INVESTIGATOR AWARD AND LEICHTUNG FAMILY INVESTIGATOR DESIGNATION FROM THE BRAIN & BEHAVIOR RESEARCH FOUNDATION IN 2018. THIS AWARD SUPPORTS DR. SANJANA'S "HUMAN NEURONS IN A DISH" APPROACH OF USING CRISPR GENE-EDITING GUIDE RNA LIBRARIES TO IDENTIFY CHANGES IN NEURONAL GENE EXPRESSION, WITH THE GOAL OF HELPING TO DESIGN AND IMPROVE THERAPIES. DR. SANJANA EARNED AN ADDITIONAL HONOR BY BEING SELECTED FOR THE FOUNDATION'S RESEARCH PARTNERS PROGRAM AS A LEICHTUNG FAMILY INVESTIGATOR. DR. SANJANA WAS ALSO JOINT LEAD RESEARCHER WITH INVESTIGATORS FROM BOSTON CHILDREN'S HOSPITAL ON A STUDY OF THREE CHILDREN FROM TWO UNRELATED FAMILIES THAT ADVANCED UNDERSTANDING OF RARE VARIANTS IN THE AUTISM SPECTRUM DISORDER KNOWN AS ANGELMAN SYNDROME. THE TEAM'S REPORT WAS PUBLISHED IN 2018 BY "THE AMERICAN JOURNAL OF MEDICAL GENETICS." TECHNOLOGY INNOVATION --------------------- TODAY, THERE ARE NUMEROUS EXCITING CLINICAL USES FOR GENOMIC INFORMATION, YET SUCH INFORMATION HAS TO BE GENERATED AND INTERPRETED IN A TIMELY, SCALABLE, AND HIGH-QUALITY FASHION IN ORDER TO SPEED AND IMPROVE THE DELIVERY OF RESULTS TO RESEARCHERS AND CLINICIANS. NYGC'S TECHNOLOGY INNOVATION LABORATORY IS A CREATIVE, MULTIDISCIPLINARY HUB WHERE SCIENTISTS ARE DEVELOPING AND DEPLOYING NEXT-GENERATION SEQUENCING METHODS, TECHNOLOGIES AND TOOLS THAT LEAD TO SCIENTIFIC ADVANCES AND NEW INSIGHTS AND THERAPIES FOR PATIENTS. THE TECHNOLOGY INNOVATION LABORATORY IS DEDICATED TO GENERATING NEW TECHNOLOGIES, PROTOCOL DEVELOPMENT, EQUIPMENT EVALUATION, AND INFORMATICS TOOL DEVELOPMENT/INTEGRATION. NYGC SCIENTISTS ARE DEVELOPING VARIOUS NOVEL TECHNOLOGIES TO SPEED UP, REDUCE COSTS OF AND DECREASE THE HANDLING OF NEXT-GENERATION LIBRARY PREPARATION REACTIONS OF NEXT-GENERATION LIBRARY PREPARATION REACTIONS. RESEARCH SEQUENCING ------------------- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST FIVE YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED TENS OF THOUSANDS OF WHOLE GENOME SAMPLES. IN 2018, THE CENTER ACQUIRED NOVASEQ SYSTEMS SEQUENCERS TO SUPPLEMENT ITS STABLE OF HISEQ X AND 2500 SEQUENCERS. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREATER SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGCS RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR SCIENTIFIC DIRECTOR, SEQUENCING OPERATIONS (WHO BECAME SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES IN JANUARY 2019), OPTIMIZED A POOLING AND LOADING SCHEME FOR WHOLE GENOME SEQUENCING ON NOVASEQ SEQUENCERS THAT MAXIMIZES THE NUMBER OF SAMPLES SEQUENCED PER RUN AND REDUCES REAGENT COSTS PER SAMPLE. THE LAB ALSO DEVELOPED A NEW WHOLE GENOME BISULFITE SEQUENCING METHOD IN COLLABORATION WITH THE ALBERT EINSTEIN COLLEGE OF MEDICINE. THIS NEW METHOD IMPROVES THE EFFICIENCY AND COST OF BISULFITE CONVERSION OF DNA, A STANDARD APPROACH TO STUDY DNA METHYLATION, A FORM OF DNA MODIFICATION THAT PLAYS AN IMPORTANT ROLE IN AN ARRAY OF BIOLOGICAL PROCESSES. THE TEAMS DESCRIPTION OF THE METHOD WAS PUBLISHED IN "GENOME RESEARCH" IN 2018. |
| EDUCATION | ----------- AS PART OF NYGC'S EDUCATIONAL MISSION, IT HOSTED MANY SCIENTIFIC MEETINGS, WORKSHOPS, CONFERENCES AND LECTURES IN 2018. THE NYGC GENOME CENTER CANCER GROUP ORGANIZES THE NEW YORK CANCER GENOMICS RESEARCH NETWORK MEETINGS THAT ARE HELD ON THE FIRST TUESDAY OF EVERY MONTH DURING THE ACADEMIC YEAR, BRINGING TOGETHER LEADING RESEARCHERS AND CLINICIANS FROM NYGC MEMBER AND OTHER KEY ACADEMIC INSTITUTIONS. THE MEETINGS ARE INTENDED PRIMARILY FOR PRINCIPAL INVESTIGATORS AND THEIR TRAINEES IN THE NEW YORK REGION. NYGC HELD "EVENING TALKS," A LECTURE SERIES FOR THE GENERAL PUBLIC ON ADVANCES IN GENOMIC SCIENCE, SPONSORED BY THE NEW YORK CITY COMMUNITY TRUST-PYEWACKET FUND. THESE TALKS ARE DESIGNED TO MAKE THE LATEST GENOMIC RESEARCH DISCOVERIES MORE ACCESSIBLE AND UNDERSTANDABLE FOR THE GENERAL PUBLIC. THESE WELL-ATTENDED LECTURES (AVERAGING 150 GUESTS PER EVENT) FEATURE PANELS OF LEADING RESEARCHERS AND CLINICIANS FROM NYGC AND/OR MEMBER INSTITUTIONS. IN 2018, NYGC HELD TALKS ON RARE DISEASE GENOMICS, THE LATEST ADVANCES IN DNA ANALYSIS, AND SPACE GENOMICS. NYGC HOSTED "FIVE POINTS" LECTURES FOR THE SCIENTIFIC COMMUNITY, FEATURING LEADING RESEARCHERS FROM AROUND THE COUNTRY AND ABROAD. THESE LECTURES BRING LEADING SCIENTISTS TO NYGC FOR IN-DEPTH DISCUSSIONS OF THEIR WORK WITH RESEARCHERS, CLINICIANS, AND STUDENTS FROM NYGC, ITS MEMBER INSTITUTIONS, AND OTHERS IN THE SCIENTIFIC COMMUNITY. IN FALL 2018, NYGC HOSTED ITS SECOND "GENOMIC INNOVATION" COURSE, A 14-WEEK PROJECT-FOCUSED COURSE DEVELOPED BY NYGC CORE FACULTY MEMBERS NEVILLE SANJANA, PHD AND TUULI LAPPALAINEN, PHD. THE FOUR-CREDIT CLASS, THE FIRST-EVER GRADUATE-LEVEL COURSE TO BE HOSTED BY NYGC, INTRODUCED STUDENTS TO CUTTING-EDGE TECHNOLOGIES AND APPLICATIONS IN GENETICS AND GENOMICS AND THEIR RESPONSIBLE USE IN SCIENCE AND SOCIETY. GRADUATE STUDENTS FROM COLD SPRING HARBOR LABORATORY, COLUMBIA UNIVERSITY, ALBERT EINSTEIN COLLEGE OF MEDICINE, MOUNT SINAI SCHOOL OF MEDICINE (MSSM) MSKCC, NYU, THE ROCKEFELLER UNIVERSITY, STONY BROOK UNIVERSITY AND WCM COULD RECEIVE CREDIT FOR THE CLASS THROUGH THEIR REGISTRAR'S OFFICE AND THE COURSE WAS OFFICIALLY LISTED IN THE COURSE CATALOGS OF COLUMBIA, NYU, AND EINSTEIN. THE FIRST CLASS INCLUDED STUDENTS FROM COLUMBIA, EINSTEIN, MSKCC, NYU, MSSM AND WCM. NYGC HELD ITS 4TH SEQUENCING INFORMATICS WORKSHOP IN NOVEMBER 2018. THE WEEK-LONG EVENT CONSISTED OF LECTURES FROM NYGCS BIOINFORMATICS TEAM AND HANDS-ON EXERCISES. STUDENTS WERE INTRODUCED TO A VARIETY OF SEQUENCING INFORMATICS TOPICS, INCLUDING SEQUENCING EXPERIMENT DESIGN CONSIDERATIONS, STANDARD DATA VISUALIZATION TECHNIQUES, RNA-SEQ DATA ANALYSIS AND STRUCTURAL VARIATION CALLING. JLABS PARTNERSHIP ------------------ IN JUNE 2018, NYGC, JOHNSON & JOHNSON INNOVATION LLC AND NEW YORK STATE CELEBRATED THE OPENING OF JLABS @ NYC, A NEW 30,000 SQUARE-FOOT FACILITY ON THE NYGC'S THIRD FLOOR THAT IS HOME TO 28 LIFE SCIENCE STARTUPS IN THE BIOTECH, PHARMACEUTICAL, MEDICAL DEVICE AND CONSUMER AND HEALTH TECH SECTORS. THE INITIATIVE SUPPORTS THE GROWTH OF HEALTH CARE SOLUTIONS IN THE REGION BY PROVIDING A COMPREHENSIVE COMMERCIALIZATION VEHICLE FOR EMERGING LIFE SCIENCE COMPANIES. JLABS' SUPPORT OF TALENTED SCIENTISTS IN NYC AS THEY TAKE THEIR INNOVATIVE IDEAS TO MARKET ALIGNS WITH NYGC'S MISSION OF FOSTERING INTELLECTUALLY VIBRANT COLLABORATIONS THAT ADVANCE THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS AGAINST HUMAN DISEASE. ORGANIZATION MEMBERS FORM 990, PART VI, SECTION A, LINE 6: AS OF DECEMBER 31, 2018, THE CENTER HAD A TOTAL OF 17 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND FIVE ASSOCIATE MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE; AND (5) PRINCETON UNIVERSITY |
| ORGANIZATION MEMBERS - DECISION MAKING | FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGCS BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS. |
| FORM 990 REVIEW | FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE SENIOR VICE PRESIDENT, FINANCE & ADMINISTRATION; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND PRESIDENT & COO, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. |
| CONFLICT OF INTEREST POLICY & REVIEW | FORM 990, PART VI, SECTION B, LINE 12C: NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE TO WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. |
| COMPENSATION REVIEW AND APPROVAL | FORM 990, PART VI, SECTION B, LINE 15: FOR THE ORGANIZATIONS TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT IN LATE 2016 TO REVIEW SENIOR MANAGEMENT'S COMPENSATION. RESULTS OF THIS REVIEW WERE PROVIDED TO THE AD-HOC COMPENSATION COMMITTEE IN EARLY 2017. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT (CHERYL MOORE, CAROL ASHE, CHRISTOPHER DUIGNAN, KATHLEEN MCGOVERN KEARNS, ELIZABETH O'BRIEN, AND MATTHEW PELO) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE MET AGAIN IN DECEMBER 2017 AND DISCUSSED SENIOR MANAGEMENT COMPENSATION. SENIOR MANAGEMENT DID NOT RECEIVE MERIT INCREASES IN 2018. TWO MEMBERS OF SENIOR MANAGEMENT RECEIVED DISCRETIONARY BONUSES IN 2018 (ELIZABETH O'BRIEN AND MATTHEW PELO), WHICH WERE APPROVED BY THE AD-HOC COMPENSATION COMMITTEE IN DECEMBER 2017. THE PRESIDENT & COO DECLINED A MERIT INCREASE AND HER COMPENSATION WAS UNCHANGED. |
| DOCUMENT DISCLOSURE | FORM 990, PART VI, SECTION C, LINE 19: NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. COMPENSATION OF OFFICERS AND DIRECTORS FORM 990, PART VII, SECTION A IN 2018, TOM MANIATIS, PHD., WAS EMPLOYED BY AN UNRELATED ENTITY AND CONTRIBUTED 15% OF HIS TIME TO WORK ON A NATIONAL INSTITUTES OF HEALTH GRANT AWARDED TO NYGC TO CREATE A CENTER FOR COMMON DISEASE GENOMICS. INDEPENDENT CONTRACTORS FORM 990, PART VII, SECTION B NYGC was reimbursed by either a grant from the New York State Urban Development Corporation (Empire State Development) or J&J Services (J&J) for nearly all of the vendor compensation described in part vii because the services conducted by the vendors related to JLABS (see Form 990, Schedule O at page 68 for JLABS description). -Turner Construction Company was the general contractor for the JLABS buildout. All of the compensation listed in part vii was reimbursed by the Empire State Development grant. -Gensler was the architect for the JLABS buildout. All of the compensation listed in part vii was reimbursed by the Empire State Development grant. -P.J. Mechanical Service & Maintenance Co. provided engineering services to NYGC and JLABS. A portion of the compensation listed in part vii related to services performed for JLABS was reimbursed to NYGC by either J&J or the Empire State Development grant. -Guardian Services Industries provided cleaning services to NYGC and JLABS. A portion of the compensation listed in part vii related to services performed for JLABS was reimbursed to NYGC by J&J. -T.E.C. Systems Inc. provided preventative maintenance services to NYGC and JLABS. A portion of the compensation listed in part vii related to services performed for JLABS was reimbursed to NYGC by either J&J or the Empire State Development grant. NET ASSET CLASSIFICATION FORM 990, PART X, LINES 27-29: THE FASB ISSUED ACCOUNTING STANDARDS UPDATE (ASU) 2016-14 NOT-FOR-PROFIT ENTITIES (TOPIC 958), PRESENTATION OF FINANCIAL STATEMENTS OF NOT-FOR-PROFIT ENTITIES, WHICH AMONG OTHER THINGS, CHANGES HOW NOT-FOR-PROFIT ENTITIES REPORT NET ASSET CLASSES. THE SIGNIFICANT REQUIREMENTS OF ASU 2016-14 INCLUDE REDUCTION IN THE NUMBER OF NET ASSET CLASSES FROM THREE TO TWO: WITH DONOR RESTRICTIONS (FORMERLY REPORTED AS TEMPORARILY RESTRICTED NET ASSETS) AND WITHOUT DONOR RESTRICTIONS (FORMERLY REPORTED AS UNRESTRICTED NET ASSETS). THE 2018 FORM 990, PART X WAS NOT UPDATED TO REFLECT THE CHANGE IN NET ASSET CLASS TERMINOLOGY; THEREFORE, NYGC HAS REPORTED NET ASSETS WITHOUT DONOR RESTRICTION AS UNRESTRICTED NET ASSETS AND NET ASSETS WITH DONOR RESTRICTIONS AS TEMPORARILY RESTRICTED NET ASSETS. |
| Software ID: | |
| Software Version: |